GE HealthCare TechnologiesGEHC
Recorded

GE HealthCare Technologies 2026 Q2 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ2 2026Duration1 hr 1 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day. Thank you for standing by. Welcome to the GE HealthCare second quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carolyn Borders, Chief Investor Relations Officer. Ma'am, please go ahead. Thanks, operator.

Carolynne BordersChief Investor Relations Officer

Good morning. Welcome to GE HealthCare's second quarter 2026 earnings call. I'm joined by our President and CEO, Peter Arduini, Vice President and CFO, Jay Saccaro, and our Controller and Chief Accounting Officer, George Newcomb. Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website. During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. With that, I'll hand the call over to Peter.

Peter ArduiniPresident and CEO

Thanks, Carolyn. Good morning. Thank you for joining us today. We were pleased with our strong performance in the second quarter. Orders increased 11%, with strong backlog, which grew $2.6 billion year-over-year, and booked a bill of 1.15 times, all of which were at record levels. We're seeing healthy end market demand in all three of our segments and across geographies, reflected in the growth of our differentiated products and solutions that improve clinical outcomes and productivity. This sentiment was once again reflected in our most recent survey of top U.S. customers. We're increasingly becoming a key productivity enabler for our customers as they navigate capacity constraints and workflow challenges.

Peter ArduiniPresident and CEO

At the same time, the substantial changes that we've made in our commercial organizations and progress on our new innovations, many of which are AI-enabled, strengthen our competitive position and are delivering results. We've launched several new products from our pipeline with more to come. These products position us well to contribute meaningfully through the balance of the year and beyond. We're also seeing continued traction in our service businesses, strengthening our recurring revenue base and creating additional value for customers. Fundamentally, it's the sum of all of these parts that gives us confidence in the remainder of the year and our medium-term outlook. Revenue growth in the quarter was led by strength in Pharmaceutical Diagnostics and Advanced Imaging Solutions. Patient Care Solutions performance remained challenged.

Peter ArduiniPresident and CEO

We're actioning improvement initiatives via our business system, Heartbeat, with a focus on increasing shipment velocity and backlog conversion of our monitoring and anesthesia product lines to deliver PCS revenue and margin improvement in the second half. A bright spot in the quarter was the strong PCS orders growth, particularly in monitoring, driven by our new platforms and recent sales force realignment. As we focus on accelerating recovery in this business, a comprehensive review of the strategic options is underway to determine the best path to maximize long-term growth and value, including continued ownership, a sale, and other value-enhancing transactions. This is a business with depth and breadth that touches many areas within health systems. We have a healthy pipeline of new products in anesthesia and monitoring, as well as digital offerings expected to be introduced this year and in 2027. Moving to slide four. Let's look at how we're delivering on our growth strategy, starting with how we enable precision care.

Peter ArduiniPresident and CEO

D3 brings together smart devices and drugs, a disease state-focused and digital capabilities, particularly AI. Heartbeat helps us align customer needs, product development, sales, and service capabilities more effectively. Together, they help us bring innovative products to market faster and strengthen customer relationships while improving the margin profile of the portfolio over time. Our D3 strategy is resonating with customers, and their interest in our differentiated solutions is reflected in our strong orders growth in the quarter, including broad-based contributions from ultrasound, MR, CT, patient monitoring, radiopharmaceuticals, and interventional labs, among others. This aligns to the global demand backdrop we're seeing for our technologies and underscores how our differentiated innovations and field teams are winning in the market.

Peter ArduiniPresident and CEO

In the U.S., we're seeing strong interest in Photonov Spectra, our photon-counting CT platform, and we expect CE marking in the second half of 2026, which will expand our opportunity in Europe. We've also received great customer feedback on TrueFidelity DL, our latest deep learning CT software upgrade that enables nearly double the image resolution across the installed base. Like AIR Recon DL, this is another good example of how we are using AI to enhance the clinical value of existing systems while giving customers another pathway to enhance performance. We also offer this as a subscription model, which brings recurring revenue. Together, these innovations highlight how we're expanding the value of our CT portfolio through new products and software innovations that appeal to customers. In PDx, we had a strong quarter in contrast media and robust growth in U.S. radiopharmaceuticals.

Peter ArduiniPresident and CEO

This reflects the growing demand for advanced imaging that requires the breadth of our PDx portfolio. As an example, Vizamyl, our amyloid PET imaging agent, had strong double-digit revenue growth in the quarter, reflecting an increase in therapy adoption and an evolving Alzheimer's eco-care system, which includes broader diagnostic capabilities to identify and evaluate at-risk patients. Additionally, we are on track with our Flyrcado ramp. In the quarter, we delivered 545 doses for the week ending July 24th. This is approximately a 40% increase over April levels. We onboarded more customers this quarter, which we expect will lead to increased utilization in the second half of the year. Customer feedback and acceptance remain strong. Looking to the second half, we remain focused on continuing to build momentum and these important indicators of our long-term growth trajectory.

Peter ArduiniPresident and CEO

We remain confident in our medium-term target of $500 million or more in annual revenues by 2028. Moving to business optimization. We continue to prioritize additional cost and price actions as we navigate a dynamic macro environment. We lead the industry in bringing AI to customers, and we're also equally focused on using AI inside the company to improve productivity, simplify work, and strengthen our supply chain so teams can spend more time on activities that create the greatest value for our customers. Since implementing the operational changes to create AIS in Global Markets, we have significantly increased our customer focus with channel changes that were completed in the second quarter. The AIS structure allows us to be a more nimble and agile organization.

Peter ArduiniPresident and CEO

Before I turn the call over to Jay to review our financial results, I'd like to take a moment to thank him for his partnership and contributions to GE HealthCare over the past three years. Jay's helped build a strong financial organization, instill greater financial discipline across the company, and has been an important partner as we've executed our strategy. We're grateful for his leadership and impact that he's had on the business, and we wish you all the best in your next endeavor. During this transition, I have full confidence in George Newcomb, our incoming interim CFO, who has extensive experience. With that, I'll turn the call over to Jay to review our financial results.

Jay SaccaroVP and CFO

Jay? Thanks, Pete. I really appreciate the partnership, it's been a privilege to work alongside you in such a talented organization.

Jay SaccaroVP and CFO

I'm also proud of all that we've accomplished together, I have great confidence in the team and the strong foundation we've built to continue executing on the strategy, delivering for patients, customers, and shareholders. With that, I'll turn to our second quarter financial performance on slide five. We delivered revenue of $5.3 billion, representing 3.5% organic growth year-over-year, in line with our expectations. On a reported basis, we saw revenue growth across all regions. We had solid performance in product and service revenues at 4.7% and 7.7% growth, respectively. Service growth benefited from operational performance as well as contributions from the recent Intelerad acquisition. Organic orders growth was robust, up 11.1% year-over-year, the highest since our spin.

Jay SaccaroVP and CFO

We saw orders growth across all of our segments, with particular strength in several of our longer cycle products in radiology, which represents our former Imaging business. These products have longer sales conversion cycles, we expect these orders to contribute to revenue more meaningfully in 2027. Book to bill was 1.15 times, also our highest since the spin, we exited the quarter with a record backlog of $23.9 billion, up $2.6 billion year-over-year and $2.1 billion sequentially. Approximately one quarter of the sequential increase is in product backlog, while the balance relates to multi-year service agreements that convert to revenue over time. Adjusted EBIT of $750 million included $23 million in recognized refunds from IEEPA tariffs incurred in the first quarter of 2026. Adjusted EBIT margin of 14.2% was down 40 basis points year-over-year.

Jay SaccaroVP and CFO

We delivered adjusted EPS of $1.13 in the quarter, up 6.6% year-over-year. Adjusted EPS benefited from $0.04 of tariff refunds and $0.02 due to a lower tax rate year-over-year. Even when adjusting for these contributions, performance exceeded our expectations. Lastly, our free cash flow was $68 million in the quarter, which includes tariff refunds of $107 million. For this quarter, given macro dynamics, we thought it would be helpful to include additional details on our margin performance on slide six. Adjusted EBIT margin was 14.2%, down 40 basis points year-over-year. Let's walk through the drivers. First, year-over-year margin was negatively impacted by the challenging quarter in PCS, as well as incremental inflationary costs from memory chips, oil and freight, and other components. Despite these challenges, strong commercial execution drove volume growth, providing a margin tailwind year-over-year.

Jay SaccaroVP and CFO

Heartbeat is helping us better connect our product and commercial teams as we bring our latest innovations to market, supporting both growth and margin expansion. A great example is our Vivid Pioneer ultrasound, which leverages a platform approach to achieve a lower manufactured cost, coupled with differentiated AI capabilities that drive higher pricing. This product is performing better than we expected and has allowed us to deliver a significantly higher gross margin than the prior platform. This development model is replicated across all of our products in our new wave of innovation. Meanwhile, we're focusing on daily management to enable incremental price and cost actions to help offset inflation impacts in 2026.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day